Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants.

Molecular diagnosis & therapy - 1 Jun 2020

Pestinger Valerie, Smith Matthew, Sillo Toju, Findlay John M, Laes Jean-Francois, Martin Gerald, Middleton Gary, Taniere Phillipe, Beggs Andrew D

Abstract excerpt

INTRODUCTION: The identification of tumour mutational burden (TMB) as a biomarker of response to programmed cell death protein 1 (PD-1) immunotherapy has necessitated the development of genomic assays to measure this. We carried out comprehensive molecular profiling of cancers using the Illumina TruSight Oncology 500 (TSO500) panel and compared these to whole-genome sequencing (WGS). METHODS: Cancer samples...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Computational Biology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Copy Number Variations

Share to High-Throughput Nucleotide Sequencing

Share to Immune Checkpoint Inhibitors

Share to Microsatellite Instability

Share to Neoplasms

Share to Whole Genome Sequencing

Source

Open in PubMed Open full text

Identifiers

PMID: 32306292
DOI: 10.1007/s40291-020-00462-x
PMCID: PMC7264086

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants.PMID 32306292Read ↗

Use of an integrated pan-cancer oncology enrichment NGS assay to measure tumour mutational burden and detect clinically actionable variantsSemantic proximity Read ↗

TruSight Oncology 500: Enabling Comprehensive Genomic Profiling and Biomarker Reporting with Targeted SequencingSemantic proximity Read ↗

Validation of a targeted sequencing panel with automatic analysis system for clinical decision support in cancer therapySemantic proximity Read ↗

Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing.Semantic proximity Read ↗

Target-enhanced whole-genome sequencing (TE-WGS) shows clinical validity equivalent to commercially available targeted oncology panelSemantic proximity Read ↗

Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centreSemantic proximity Read ↗

Diagnostic Validation of a Comprehensive Targeted Panel for Broad Mutational and Biomarker Analysis in Solid TumorsSemantic proximity Read ↗

Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels.Semantic proximity Read ↗

Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panelSemantic proximity Read ↗

Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.Semantic proximity Read ↗

Analytical and Clinical Validation of a Target-Enhanced Whole Genome Sequencing-Based Comprehensive Genomic Profiling Test.Semantic proximity Read ↗

A real-world pan-cancer catalogue of mutational signatures from 111,711 tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.